Dihydroergocristine mesylatePartial dopamine receptor agonist. Also partial adrenergic agonist and 5-HT antagonist CAS# 24730-10-7 |
- MLN9708
Catalog No.:BCC2091
CAS No.:1201902-80-8
- MG-115
Catalog No.:BCC1237
CAS No.:133407-86-0
- Clasto-Lactacystin β-lactone
Catalog No.:BCC1224
CAS No.:154226-60-5
- CEP-18770
Catalog No.:BCC2093
CAS No.:847499-27-8
- Carfilzomib (PR-171)
Catalog No.:BCC1145
CAS No.:868540-17-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 24730-10-7 | SDF | Download SDF |
PubChem ID | 444034 | Appearance | Powder |
Formula | C36H45N5O8S | M.Wt | 707.84 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 25 mM in DMSO | ||
SMILES | CC(C)C1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O | ||
Standard InChIKey | SPXACGZWWVIDGR-SPZWACKZSA-N | ||
Standard InChI | InChI=1S/C35H41N5O5.CH4O3S/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34;1-5(2,3)4/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41);1H3,(H,2,3,4)/t23-,25-,27-,28+,29+,34-,35+;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 5-HT receptor antagonist; partial agonist at adrenergic and dopaminergic receptors. |
Dihydroergocristine mesylate Dilution Calculator
Dihydroergocristine mesylate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.4127 mL | 7.0637 mL | 14.1275 mL | 28.255 mL | 35.3187 mL |
5 mM | 0.2825 mL | 1.4127 mL | 2.8255 mL | 5.651 mL | 7.0637 mL |
10 mM | 0.1413 mL | 0.7064 mL | 1.4127 mL | 2.8255 mL | 3.5319 mL |
50 mM | 0.0283 mL | 0.1413 mL | 0.2825 mL | 0.5651 mL | 0.7064 mL |
100 mM | 0.0141 mL | 0.0706 mL | 0.1413 mL | 0.2825 mL | 0.3532 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fimasartan
Catalog No.:BCC5552
CAS No.:247257-48-3
- Daphnezomine B
Catalog No.:BCN5113
CAS No.:247078-43-9
- 6-Deoxy-9alpha-hydroxycedrodorin
Catalog No.:BCN5112
CAS No.:247036-52-8
- 7beta-Methoxyrosmanol
Catalog No.:BCN7965
CAS No.:24703-38-6
- Weinreb Linker
Catalog No.:BCC2836
CAS No.:247021-90-5
- NVP DPP 728 dihydrochloride
Catalog No.:BCC2365
CAS No.:247016-69-9
- Isomangiferin
Catalog No.:BCN2528
CAS No.:24699-16-9
- Leonurine hydrochloride
Catalog No.:BCN6286
CAS No.:24697-74-3
- Chlorouvedalin
Catalog No.:BCN4664
CAS No.:24694-80-2
- Uvedalin
Catalog No.:BCN4665
CAS No.:24694-79-9
- Senegenin
Catalog No.:BCN5899
CAS No.:2469-34-3
- Derrisisoflavone B
Catalog No.:BCN3955
CAS No.:246870-75-7
- Leonurin monohydrochloride
Catalog No.:BCN8304
CAS No.:24735-18-0
- SB 328437
Catalog No.:BCC6056
CAS No.:247580-43-4
- Beta-Peltoboykinolic acid
Catalog No.:BCN6635
CAS No.:24778-48-1
- 1,3-Bis(4-aminophenoxy)benzene
Catalog No.:BCC8418
CAS No.:2479-46-1
- Estriol 3-glucuronide
Catalog No.:BCN2239
CAS No.:2479-91-6
- N-Me-Val-OH.HCl
Catalog No.:BCC2612
CAS No.:2480-23-1
- H-N-Me-Ser-OH.HCl
Catalog No.:BCC3352
CAS No.:2480-26-4
- N2-Methyl-L-arginine
Catalog No.:BCC6032
CAS No.:2480-28-6
- Boc-Orn(Z)-OH
Catalog No.:BCC3430
CAS No.:2480-93-5
- (-)-Epiafzelechin
Catalog No.:BCN5114
CAS No.:24808-04-6
- H-Cys(tBu)-OH.HCl
Catalog No.:BCC2910
CAS No.:2481-09-6
- Reserpinine
Catalog No.:BCN3490
CAS No.:24815-24-5
Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma.[Pubmed:16379666]
Curr Drug Metab. 2005 Dec;6(6):519-29.
Dihydroergocristine (DHEC) is a semi-synthetic drug mainly used for age-related cognitive impairment. In this study, its major metabolite 8'-hydroxy-dihydroergocristine (8'-OH-DHEC) was produced in incubates of a bovine liver preparation using Dihydroergocristine mesylate (DHECM) as substrate. Purification was achieved by flash silica gel column and reverse phase liquid chromatographies, and identification was based on accurate molecular mass measurements, mass fragmentation spectra and NMR ((1)H/(13)C) chemical shifts. By using the substance produced in vitro, a fast, sensitive, specific and robust LC/MS/MS method for the simultaneous determination of DHEC and its major metabolite in human plasma was developed and validated. Bromocriptine was used as internal standard and limits of quantification for DHEC and 8'-OH-DHEC were 10 pg/ml and 20 pg/ml, respectively. Pharmacokinetic parameters were investigated on 12 male healthy volunteers to whom a single dose of 18 mg DHECM was administered in tablets (Iskevert). The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h. The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h. Dosing of 18 mg DHECM was well tolerated, causing no adverse events.
Dihydroergocristine and memory alterations of aged male rats.[Pubmed:3147464]
Pharmacol Biochem Behav. 1988 Aug;30(4):961-5.
The ergot alkaloid derivative dihydroergocristine (DHECS) was injected acutely or subchronically to aged male rats of the Sprague-Dawley strain, 26 months old, at the dose of 0.05 or 0.1 mg/kg. Learning and memory ability of the animals were studied with tests of avoidance behavior. The acquisition of active avoidance behavior was studied with the shuttle-box and pole-jumping tasks. In the latter, the extinction of active avoidance behavior was also studied. A step-through type of passive avoidance task was used to examine the retention of passive avoidance responses. The acquisition of the active avoidance behavior and the retention of the passive avoidance response were reduced in aged animals as compared to those of young animals. Acute treatment of old rats with DHECS was followed by a facilitation of acquisition of active avoidance behavior in the shuttle box and of retention of passive avoidance responses in the dark box. The effect on the acquisition and extinction of pole-jumping behavior after a single injection of DHECS at the beginning of the acquisition session was restricted to the first acquisition trial. A more potent effect on the acquisition of the shuttle-box behavior and on the retention of passive avoidance reaction was found in animals treated subchronically with the ergot derivative (0.05 and 0.1 mg/kg for 10 days). These rats also showed a facilitation of acquisition and an inhibition of extinction of pole jumping behavior.